Thus, we assessed whether varlitinib can reduce tauopathy and found that varlitinib significantly decreased tau phosphorylation at Thr212/Ser214 and Thr231 (AT180) as well as tau kinase DYRK1A levels in 3-month-old PS19 mice (Figure 7). Here, DYRK1A is linked to tauopathy.